New hope for immunotherapy side effects: blood filtering may replace steroids

NCT ID NCT07619898

Not yet recruiting Disease control Sponsor: Therakos LLC Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a treatment called extracorporeal photopheresis (ECP) for people with advanced melanoma who develop severe colitis or hepatitis from immunotherapy. ECP filters a patient's blood, treats it with a light-activated drug, and returns it to the body. The trial compares ECP to standard second-line drugs like infliximab or vedolizumab. About 112 participants will be enrolled to see if ECP can help them stop steroids and control the side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: extracorporeal photopheresis (ECP) with methoxsalen
What this could lead to: If successful, ECP could offer a new steroid-free option for managing severe gut or liver side effects from melanoma immunotherapy.
What could go wrong: This is a phase 2 trial with only 112 participants, so results are preliminary. ECP is a complex blood-filtering procedure and may not work better than existing drugs.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autoimmune hepatitis colitis hepatitis melanoma metastatic melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLITIS HEPATITIS MELANOMA (SKIN CANCER)

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.